IMNN logo

IMNN Imunon, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.54
-0.03 (-5.22%)

Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently…

Market Cap: $3.47Mwww.imunon.com

Price

No data yet.

Social Signal Score

48
5d
—
30d
50
2 mentions
—
60d
45
4 mentions
—
90d
50
9 mentions
—
news: 9

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 1Sell 0Strong Sell 0
Avg price target$10+1767.4%
Low $10Median $10High $10
Current Consensus

Revenue

$0.00-100.00%
$0.00$41.7K$83.3K$125.0K
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-7.13
$-9.54–$-3.29
3 analysts
FY2026
$-2.36
$-2.48–$-2.24
2 analysts
FY2027
$-1.85
$-2.11–$-1.59
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Stacy R. Lindborg
Sector
Healthcare
Industry
Biotechnology
Employees
20
Beta
2.08
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-54.03
www.imunon.com